ALDX Aldeyra Therapeutics, Inc.Stock Price & Overview
$3.73
Charts
Quant Ranking
ALDX Analysis
ALDX News
Latest Headlines
Ratings Summary
People Also Follow
Similar to ALDX
ETFs Holding ALDX
ALDX Company Profile
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Revenue
ALDX Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Profitability
Momentum
Capital Structure
Dividends
ALDX Ownership
ALDX Peers
Risk
Technicals
ALDX Transcripts
Investor Presentations
ALDX SEC Filings
Press Releases
ALDX Income Statement
ALDX Balance Sheet
ALDX Cash Flow Statement
ALDX Long Term Solvency
Discover More
You may be interested in: